Novel Treatments of Myelodysplastic Syndromes

February 10, 2019

As an associate editor on the ASCO Post editorial Board, Syed Ali Abutalib, MD, Assistant Medical Director of the Stem Cell Transplant and Cell Therapy Program at Cancer Treatment Centers of America® (CTCA), Chicago, provides regular updates and key findings, along with a fellow colleague, on clinical cancer research, policy news, patient care, and clinical practice issues.

In this review, the doctors provide updates on seven different studies on new therapeutics in myelodysplastic syndromes (MDS), as part of The ASCO Post’s continued coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition. Among the treatments highlighted here are the erythroid maturation agent luspatercept, the Toll-like receptor 2 antibody tomaralimab, the XPO1 inhibitor selinexor, and the DNA methyltransferase inhibitor guadecitabine.

Read more here